Top Industry Leaders in the Facial Paralysis Market
Latest Facial Paralysis Companies Updates:
ReNeuron Receives Positive Phase 2 Data for ReNderiv, A Stem Cell Therapy for Bell's Palsy: In October 2023, ReNeuron announced promising results from a Phase 2 trial testing their
ReNderiv stem cell therapy for facial paralysis caused by Bell's palsy. If further trials prove successful, it could offer a novel treatment option for patients who experience incomplete recovery.
Stryker Receives FDA Approval for BoTOX® for Glabellar Lines: While not directly related to facial paralysis, the approval of BoTOX® for glabellar lines (frown lines) by the FDA in August 2023 opens up potential avenues for its use in managing facial asymmetry caused by certain types of facial paralysis.
Medtronic Acquires AQT Aesthetics: In July 2023, Medtronic acquired AQT Aesthetics, a South Korean company known for its dermal fillers and thread lifts. This move strengthens Medtronic's presence in the aesthetics market and could potentially lead to advancements in minimally invasive treatments for facial paralysis.
List of Facial Paralysis companies in the market:
- Boston Scientific
- BioControl Medical
- Cerebomed
- Cyberonics
- Astellas Pharma Inc.
- Sucampo Pharmaceuticals
- Novartis AG